First-in-Class Agitation Treatment: Igalmi (dexmedetomidine sublingual film) is the first and only orally dissolving film approved for the acute treatment of agitation associated with schizophrenia or bipolar disorders, offering a unique, non-invasive, and rapid-acting option in a market traditionally dominated by injectables.

Proprietary AI Drug Discovery Platform: The ADAPT (AI-powered Drug Development and Discovery Platform) provides a proprietary engine for identifying new therapeutic candidates and novel uses for existing drugs, potentially accelerating drug development timelines and reducing R&D costs.

Addressing High Unmet Medical Needs: Bioxcel targets severe neuropsychiatric conditions like acute agitation, which present significant unmet needs for effective, non-invasive, and rapidly acting treatment options, leading to a substantial market opportunity for its flagship product.